UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000060874 |
|---|---|
| Receipt number | R000065227 |
| Scientific Title | Efficacy of Sacubitril/Valsartan on out-of-office blood pressure in hypertensive patients |
| Date of disclosure of the study information | 2026/03/09 |
| Last modified on | 2026/03/09 16:51:53 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Efficacy and Safety of Sacubitril/Valsartan in Hypertensive Patients
Acronym
Efficacy and Safety of Sacubitril/Valsartan in Hypertensive Patients
Scientific Title
Efficacy of Sacubitril/Valsartan on out-of-office blood pressure in hypertensive patients
Scientific Title:Acronym
Efficacy of Sacubitril/Valsartan on out-of-office blood pressure in hypertensive patients
Region
| Japan |
Condition
Condition
Hypertension
Classification by specialty
| Cardiology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
We will examine the efficacy and safety of sacubitril/valsartan in comparison with renin-angiotensin-aldosterone system inhibitors in Japanese hypertensive patients.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Comparison of home blood pressure after 3 and 6 months
Key secondary outcomes
1. Change in office blood pressure
2. Change in liner function and electrolytes
3. Change in NT-proBNP
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
All patients were switched from renin-angiotensin system inhibitor (angiotensin-converting enzyme inhibitor or angiotensin receptor II blocker) to sacubitril/valsartan. Patients were initially instructed to take sacubitril/valsartan 100 mg once daily, and dosage was gradually increased up to 200 mg once daily and continued for 24 weeks.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | < |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Hypertension
2) Switched from renin-angiotensin inhibitors to sacubitril/valsartan
3) Home blood pressure levels before switching did not achieve the target levels
4) Recording home blood pressure monitoring
Key exclusion criteria
1) Received sacubitril/valsartan less than six months.
2) Non-sinus rhythm
3) Secondary hypertension
4) Myocardial infarction and/or stroke less than 30 days
5) Receiving regular hemodialysis therapy
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | Nobuyuki |
| Middle name | |
| Last name | Takahashi |
Organization
Kansai Medical University Hori Hospital
Division name
Department of Internal and General Medicine
Zip code
572-8551
Address
8-45 Kori Hon-douri chou, Neyagawa city, Osaka 572-8551, Japan
TEL
0728325321
takahasn@kouri.kmu.ac.jp
Public contact
Name of contact person
| 1st name | Yoshio |
| Middle name | |
| Last name | Iwashima |
Organization
Osaka University
Division name
Graduate School of Medicine, Department of Geriatric and General Medicine
Zip code
565-0871
Address
#B6, 2-2, Yamadaoka, Suita city, Osaka
TEL
0668793852
Homepage URL
iwashima@geriat.med.osaka-u.ac.jp
Sponsor or person
Institute
Kansai Medical University
Institute
Department
Personal name
Funding Source
Organization
None.
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Ethical Review Board Kansai Medical University
Address
2-5-1, Sinmachi, Hirakata city, Osaka, Japan
Tel
072-804-0101
rinriirb@hirakata.kmu.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 03 | Month | 09 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
58
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2022 | Year | 01 | Month | 04 | Day |
Date of IRB
| 2025 | Year | 10 | Month | 22 | Day |
Anticipated trial start date
| 2022 | Year | 01 | Month | 04 | Day |
Last follow-up date
| 2026 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2026 | Year | 03 | Month | 09 | Day |
Last modified on
| 2026 | Year | 03 | Month | 09 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065227
